Schizophrenia

Firearm use in the not guilty by reason of insanity population is more closely related to substance use and personality disorder than psychotic or mood disorders.

Women with PCOS face increased risk of psychiatric morbidity and their children are more likely to be diagnosed with ADHD or autism.

A new study suggests the novel therapy can help empower patients with psychoses.

Risks increase when a child’s mother, versus their father has a history of homelessness.

ARISTADA is being investigated as a possible extended-release injectable suspension, as well as INVEGA SUSTENNA in patients with acute exacerbation of schizophrenia.

The drug showed improved symptoms across multiple doses in a 6-month study.

A father's age can negatively affect the social development of his child.

Dr. Stanley Caroff, Emeritus Professor CE of Psychiatry at the Philadelphia VA Medical Center, sits down with MD Magazine to explain what tardive dyskinesia is, and why it's so important for psychiatrists to be aware of this side effect in their patients taking antipsychotic medications. This is the conclusion of a two-part conversation.

FDA accepts sNDA for antipsychotic drug cariprazine.

Studying the use of targeted medicines in psychiatry is still new but early studies have shown that this could be a viable treatment option in the future for some patients in need.

In the field of oncology the use of targeted medications is becoming more commonplace to address various conditions. Research is being done in other areas of medicine, including psychiatry to see if there is more that can be done to address this patient population as well.

Compulsive behavior – to gamble, binge eat, shop, and have sex – is linked to the antipsychotic drug aripiprazole.

Results from a pilot study suggest that a technique called "Mental Contrasting and Implementation Intentions" is a promising way to promote physical activity in patients with schizophrenia spectrum disorders.

Researchers have uncovered more evidence to support the hypothesis that lead contributes to schizophrenia onset.

Immigrant populations tend to have nearly 2 times the prevalence of psychotic disorders compared to the general population of the host country.

Patients with schizoaffective disorder who were treated with paliperidone palmitate (as monotherapy and adjunctive therapy) experienced delayed time to relapse and reduced risk of relapse compared to patients treated with placebo.

According to research published in the Proceedings of the National Academy of Sciences, patients who are sensitive to d-amphetamine have a decreased likelihood of developing ADHD or schizophrenia.

Although the first clinical case associating acromegaly with schizophrenia was reported more than 60 years ago, researchers continue to ponder the association between the 2 disorders.

When encouraging and supporting patients to quit smoking, varenicline is unlikely to increase the risk of neuropsychiatric adverse events such as suicide, depression, and aggression, even in patients with pre-existing psychiatric illness.

Creating a safer environment for clinicians and patients starts with better formalized reporting of aggressive and violent behavior, and should also include more rigorous screening and assessment for risk markers of violent behavior.

Understanding and addressing these disorders can improve the patient's mental health as well as their chronic pain and other comorbid conditions. Incorporating cognitive behavioral therapy and mindfulness-based cognitive therapy into the management of chronic pain has been shown to improve pain outcomes.

New formulation associated with delayed time to impending relapse, as well as improvements on measures of symptom severity and treatment response.

New validated assessment tools allow clinicians to better assess the level of real-life functioning in patients with schizophrenia.

Prescription-only Seroquel found in over-the-counter Nurofen packages leading to recall.

A recent study indicates that traumatic brain injury may be linked to an increased risk of developing schizophrenia.